Syndax Pharmaceuticals Inc
SNDX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$858.87M
Close$
$-1.02
110.7% downside
Current Fair Value
110.7% downsideOvervalued by 110.7% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $858.87 Million |
|---|---|
| Enterprise Value | $1.31 Billion |
| Earnings per Share | $-3.29 |
| Beta | 0.37 |
| Outstanding Shares | 89,789,842 |
Return
| Return on Equity | 1219.34% |
|---|---|
| Return on Assets | -30.24% |
| Return on Invested Capital | -21.45% |
Valuation & Multiples
| P/E Ratio | -4.03 |
|---|---|
| PEG | 21.66 |
| Price to Sales | 3.18 |
| Price to Book Ratio | -9.54 |
| Enterprise Value to Revenue | 4.53 |
| Enterprise Value to EBIT | -10.7 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.45 |
| Debt to Equity | -34.31 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 2, 2026
EPS
-$0.55
Est. -$0.50Revenue
$83.30 M
Est. $81.38 MNext Earnings Call
Expected Date
February 25, 2027
EPS Estimate
-$0.52
Consensus analyst estimateRevenue Estimate
$95.10 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.10, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0963▼ 17.13% |
|---|---|
| Total Calls | 446,400▼ 4.10% |
| Total Puts | 43,000▼ 65.49% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 8.39%▼ 114.00% |
|---|---|
| Total Invested | $175.64M▼ 92.62% |
| Investors Holding | 75▼ 179.00% |
About Syndax Pharmaceuticals Inc
CEO: Arlene Morris
